Drug Approval | January 03, 2024
Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24
The company has received five final approvals
The company has received five final approvals
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
MedTech Mitra is a platform that will help the young talents of the country by holding their hands and giving them final shape to their research, knowledge and logic
The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
Subscribe To Our Newsletter & Stay Updated
